Pacritinib FDA Approval Status
Last updated by Judith Stewart, BPharm on Oct 19, 2020.
FDA Approved: No
Generic name: pacritinib
Company: CTI BioPharma Corp.
Treatment for: Myelofibrosis
Pacritinib is an investigational oral JAK2/FLT3 multikinase inhibitor in development for the treatment of myelofibrosis patients with severe thrombocytopenia.
Development Timeline for pacritinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.